P720: PROACTIVE DASATINIB DOSE REDUCTION IN THE ALLG CML 12 DIRECT STUDY BASED ON TROUGH LEVELS MINIMISE TOXICITY AND PRESERVE EFFICACY
David T Yeung(Royal Adelaide Hospital), Timothy P. Hughes(Royal Adelaide Hospital), Susan Branford(South Australia Pathology), K.-S. Tan(Princess Alexandra Hospital), Rosemary Harrup(University of Tasmania), Deborah L. White(ANZCHOG), Howard Mutsando(Toowoomba Hospital), Naranie Shanmuganathan(South Australia Pathology), Kate Burbury(The University of Melbourne), David M. Ross(Flinders Medical Centre), I. Cunningham(Concord Hospital), Campbell Tiley(Gosford Hospital), Anthony K. Mills(Princess Alexandra Hospital), Jake Shortt(The University of Melbourne), A. Soltenbeck, R. Eek, John Kwan(Westmead Hospital), David Kipp(Geelong Hospital), Andrew Grigg(The Royal Melbourne Hospital), Philip Rowlings(Calvary Mater Newcastle Hospital), Matthew Wright(The University of Western Australia), Nicholas Viiala(Liverpool Hospital)
Cited by 1
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
|New England Journal of Medicine|2019|464